Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice
Loading...
Date
2015-02-20
Authors
Melariri, Paula
Kalombo, Lonji
Nkuna, Patric
Dube, Admire
Hayeshi, Rose
Ogutu, Benhards
Gibhard, Liezl
deKock, Carmen
Smith, Peter
Wiesner, Lubbe
Journal Title
Journal ISSN
Volume Title
Publisher
Dovepress
Abstract
: Tafenoquine (TQ), a new synthetic analog of primaquine, has relatively poor
bioavailability and associated toxicity in glucose-6-phosphate dehydrogenase (G6PD)-deficient
individuals. A microemulsion formulation of TQ (MTQ) with sizes 20 nm improved the
solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area
under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min⋅µmol/L) for reference TQ and
MTQ, respectively. Average parasitemia in Plasmodium berghei-infected mice was four- to
tenfold lower in the MTQ-treated group. In vitro antiplasmodial activities against chloroquinesensitive and chloroquine-resistant strains of Plasmodium falciparum indicated no change in half
maximal inhibitory concentration, suggesting that the microemulsion did not affect the inherent
activity of TQ. In a humanized mouse model of G6PD deficiency, we observed reduction in
toxicity of TQ as delivered by MTQ at low but efficacious concentrations of TQ. We hereby
report an enhancement in the solubility, bioavailibility, and efficacy of TQ against blood stages
of Plasmodium parasites without a corresponding increase in toxicity.
Sustainable Development Goals
This research article published by Dovepress, 2015
Keywords
Microemulsion, G6PD deficiency, In vivo efficacy